Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic Clinical Trial

Official title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids

Status Completed

Clinical Trial Summary

This trial is to study Acthar Gel in participants with active systemic lupus erythematosus (SLE).

The doctor will assign eligible patients to one of two groups (like flipping a coin).

Participants will receive the treatment assigned to their group for 24 weeks:

• Acthar Gel

• Placebo Gel, which looks like Acthar Gel, but has no medicine in it.

The doctor or his staff will take measurements and ask questions to:

• see how well the gel is working

• see how safe it is for patients with SLE

Clinical Trial Description

This trial was initiated (started recruiting) in October 2016, but first patient was not enrolled (randomized) until December, 2016. ;

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic

• NCT number: NCT02953821
• Study type: Interventional
• Source: Mallinckrodt
• Status: Completed
• Phase: Phase 4
• Start date: December 16, 2016
• Completion date: October 25, 2019